Clinical and pharmacokinetic properties of a transdermal nicotine patch

Clin Pharmacol Ther. 1990 Mar;47(3):331-7. doi: 10.1038/clpt.1990.36.


We examined the pharmacokinetics of a transdermal nicotine patch and evaluated the usefulness of such a patch in a pilot smoking-cessation program. Use of the patch was associated with plasma nicotine concentrations that were comparable to smoking or to the use of other smoking-cessation devices. However, these plasma concentrations were maintained for 24 hours, and the patch appeared to be suitable for use once a day. Its use in a 6-week placebo-controlled double-blind study resulted in a significant degree of smoking cessation or in reduction of smoking activity. The findings suggest that it may be valuable to extend investigations to a larger population and that transdermal nicotine may have a useful role in smoking-cessation therapy.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Administration, Cutaneous
  • Adult
  • Humans
  • Male
  • Nicotine / administration & dosage
  • Nicotine / blood
  • Nicotine / pharmacokinetics*
  • Pilot Projects
  • Smoking Prevention*
  • Tobacco Use Disorder / metabolism
  • Tobacco Use Disorder / psychology*


  • Nicotine